Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aileron Therapeutics Inc (ALRN)

Aileron Therapeutics Inc (ALRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,378
  • Shares Outstanding, K 27,810
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,550 K
  • 60-Month Beta 2.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.39
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.23
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/06/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.24
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.26
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +52.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.41 +4.71%
on 10/16/19
1.04 -58.52%
on 09/18/19
-0.61 (-58.52%)
since 09/17/19
3-Month
0.41 +4.71%
on 10/16/19
1.05 -58.91%
on 09/17/19
-0.12 (-21.56%)
since 07/17/19
52-Week
0.41 +4.71%
on 10/16/19
2.70 -84.02%
on 10/18/18
-2.13 (-83.15%)
since 10/17/18

Most Recent Stories

More News
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer.

ALRN : 0.43 (-4.44%)
Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer's Palbociclib at the 2019 Congress of the European Society for Medical Oncology

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the presentation of interim results from its ongoing...

ALRN : 0.43 (-4.44%)
Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer's IBRANCE(R) (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology

Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, today announced that an abstract on interim Phase 2a data for...

ALRN : 0.43 (-4.44%)
Aileron Therapeutics Announces Management Change

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Don Dougherty, its current Chief...

ALRN : 0.43 (-4.44%)
Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Manuel Aivado, MD, PhD, President...

ALRN : 0.43 (-4.44%)
Aileron Therapeutics Reports Second Quarter 2019 Financial Results

-- Enrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer's IBRANCE(R) (palbociclib) in MDM2-amplified cancers ongoing and ahead of schedule. Interim data on at least 15 patients...

ALRN : 0.43 (-4.44%)
ALDX : 5.93 (+3.31%)
Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Manuel Aivado, MD, PhD, President...

ALRN : 0.43 (-4.44%)
Thinking about buying stock in Aileron Therapeutics, Atossa Genetics, NVIDIA, Seelos Therapeutics, or Xpresspa?

InvestorsObserver issues critical PriceWatch Alerts for ALRN, ATOS, NVDA, SEEL, and XSPA.

ALRN : 0.43 (-4.44%)
ATOS : 1.73 (-5.46%)
NVDA : 193.52 (-0.36%)
XSPA : 1.31 (unch)
Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that the U.S. Food and Drug Administration...

ALRN : 0.43 (-4.44%)
Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach

Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that William ("Bill") T. McKee and...

ALRN : 0.43 (-4.44%)
ALDX : 5.93 (+3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ALRN with:

Business Summary

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers...

See More

Key Turning Points

2nd Resistance Point 0.57
1st Resistance Point 0.51
Last Price 0.43
1st Support Level 0.40
2nd Support Level 0.35

See More

52-Week High 2.70
Fibonacci 61.8% 1.83
Fibonacci 50% 1.56
Fibonacci 38.2% 1.29
Last Price 0.43
52-Week Low 0.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar